Plasma Concentrations of Soluble Endoglin versus Standard Evaluation in Patients with Suspected Preeclampsia

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Rana, Sarosh ^a   Cerdeira, Ana Sofia ^a,b   Wenger, Julia ^c   Salahuddin, Saira ^a   Lim, Kee Hak ^a,d   Ralston, Steven J ^a   Thadhani, Ravi I ^c   Karumanchi, S Ananth ^a,e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Gulbenkian Program for Advanced Medical Education   (Portugal)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d Boston Maternal Fetal Medicine Group   (United States)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOGLIN;

ABNORMAL LABORATORY RESULT; ADULT; ADVERSE OUTCOME; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DELIVERY; EMERGENCY HEALTH SERVICE; FALSE POSITIVE RESULT; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PLASMA; PREDICTION; PREECLAMPSIA; PREGNANCY OUTCOME; PROTEIN BLOOD LEVEL; PROTEINURIA; SYSTOLIC BLOOD PRESSURE;

ADULT; ANTIGENS, CD; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; RECEPTORS, CELL SURFACE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84868104214     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048259     Document Type: Article

References (29)

1. ACOG practice bulletin, (2002) Diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol 99: 159-167.
2. Sibai B, Dekker G, Kupferminc M, (2005) Pre-eclampsia. Lancet 365: 785-799.
3. Ganzevoort W, Rep A, de Vries JI, Bonsel GJ, Wolf H, (2006) Prediction of maternal complications and adverse infant outcome at admission for temporizing management of early-onset severe hypertensive disorders of pregnancy. Am J Obstet Gynecol 195: 495-503.
4. Menzies J, Magee LA, Macnab YC, Ansermino JM, Li J, et al. (2007) Current CHS and NHBPEP criteria for severe preeclampsia do not uniformly predict adverse maternal or perinatal outcomes. Hypertens Pregnancy 26: 447-462.
5. Thangaratinam S, Gallos ID, Meah N, Usman S, Ismail KM, et al. (2011) How accurate are maternal symptoms in predicting impending complications in women with preeclampsia? A systematic review and meta-analysis. Acta Obstet Gynecol Scand 90: 564-573.
6. von Dadelszen P, Payne B, Li J, Ansermino JM, Broughton Pipkin F, et al. (2011) Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet 377: 219-227.
7. Powe CE, Levine RJ, Karumanchi SA, (2011) Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 123: 2856-2869.
8. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, et al. (2004) Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350: 672-683.
9. Chaiworapongsa T, Romero R, Kim YM, Kim GJ, Kim MR, et al. (2005) Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 17: 3-18.
10. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, et al. (2006) Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355: 992-1005.
11. Erez O, Romero R, Espinoza J, Fu W, Todem D, et al. (2008) The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 21: 279-287.
12. Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, et al. (2010) An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 202: 161 e161-161 e111.
13. Schiettecatte J, Russcher H, Anckaert E, Mees M, Leeser B, et al. (2010) Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia. Clin Biochem 43: 768-770.
14. Sunderji S, Gaziano E, Wothe D, Rogers LC, Sibai B, et al. (2010) Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. Am J Obstet Gynecol 202: 40 e41-47.
15. Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, et al. (2012) Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 125: 911-919.
16. Thadhani R, Kisner T, Hagmann H, Bossung V, Noack S, et al. (2011) Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 124: 940-950.
17. Chaiworapongsa T, Romero R, Savasan ZA, Kusanovic JP, Ogge G, et al. (2011) Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med 24: 1187-1207.
18. Kleinrouweler C, Wiegerinck M, Ris-Stalpers C, Bossuyt P, van der Post J, et al. (2012) Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis. BJOG 119: 778-787.
19. Ohkuchi A, Hirashima C, Matsubara S, Takahashi K, Matsuda Y, et al. (2011) Threshold of soluble fms-like tyrosine kinase 1/placental growth factor ratio for the imminent onset of preeclampsia. Hypertension 58: 859-866.
20. Roberts JM, Myatt L, Spong CY, Thom EA, Hauth JC, et al. (2010) Vitamins C and E to prevent complications of pregnancy-associated hypertension. N Engl J Med 362: 1282-1291.
21. Ohman EM, Armstrong PW, Christenson RH, Granger CB, Katus HA, et al. (1996) Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med 335: 1333-1341.
22. Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, et al. (2009) Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 361: 858-867.
23. Verlohren S, Herraiz I, Lapaire O, Schlembach D, Moertl M, et al. (2012) The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol 206: 58 e51-58.
24. Kusanovic JP, Romero R, Chaiworapongsa T, Erez O, Mittal P, et al. (2009) A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 22: 1021-1038.
25. Powers RW, Jeyabalan A, Clifton RG, Van Dorsten P, Hauth JC, et al. (2010) Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies. PLoS One 5: e13263.
26. Fisher KA, Luger A, Spargo BH, Lindheimer MD, (1981) Hypertension in pregnancy: clinical-pathological correlations and remote prognosis. Medicine (Baltimore) 60: 267-276.
27. Maynard SE, Min JY, Merchan J, Lim KH, Li J, et al. (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111: 649-658.
28. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, et al. (2006) Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12: 642-649.
29. Lindheimer MD, Kanter D, (2010) Interpreting abnormal proteinuria in pregnancy: the need for a more pathophysiological approach. Obstet Gynecol 115: 365-375.